Prospective multicenter observational the personalized therapy with clopidogrel for stenting in acute coronary syndrome regarding the genetic polymorphisms (PROTOCOL) study

Abstract

Clopidogrel remains the main antiplatelet therapy drug for patients after coronary stenting (CS) due to acute coronary syndrome (ACS). The paper contains substantiation and design of an observatory study with the purpose to test the hypothesis that high frequency of of cytochrome CYP2d9*2 polymorphism is associated with coronary stent thrombosis and with paradoxical response to clopidogrel in Siberian residents after CS due to ACS. Response to clopidogrel will be registered by means of light transmission aggregometry (turbidity method) in presence of adenosine diphosphate. Over the period of 30 days after coronary stenting, patients receiving clopidogrel will undergo 4 visits to assess antiplatelet therapy efficacy (end point - early stent thrombosis) and safety (all bleeding events), with consideration of genetic profile. Ethic support of the study

Keywords

• клопидогрел
• стентирование коронарных сосудов
• острый коронарный синдром
• персонализированная терапия
• световая трансмиссионная агрегометрии
• резистентность к клопидогрелу
• парадоксальный ответ
• генетические полиморфизмы
• обсервационное исследование
• наблюдательное исследование
• clopidogrel
• coronary stenting
• acute coronary syndrome
• personalized therapy
• light transmission aggregometry
• clopidogrel resistance
• paradoxical response
• genetic polymorphisms
• observasional study